Metastatic Colorectal Cancer



Colon and rectal cancer continue to be a common disease. Despite the availability of an effective screening test, patients continue to present frequently with Stage 4 disease (metastatic spread). The most common sites of spread are the liver and the lungs. Over the past few decades, improvement in surgical techniques as well as the availability of improved chemotherapeutic agents has improved survival and has even led to cures of patients who once would have been offered no hope. For the surgeon caring for patients with metastatic colorectal cancer, it is key to understand the importance of a multidisciplinary team approach.


Rectal Cancer Liver Metastasis Liver Resection National Comprehensive Cancer Network Lynch Syndrome 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


  1. 1.
    Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J Clin. 2012;62(1):10–29.PubMedCrossRefGoogle Scholar
  2. 2.
    Ko C, Chaudhry S. The need for a multidisciplinary approach to cancer care. J Surg Res. 2002;105(1):53–7.PubMedCrossRefGoogle Scholar
  3. 3.
    Fuchs CS, Marshall J, Barrueco J. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: updated results from the BICC-C study. J Clin Oncol. 2008;26(4):689–90.PubMedCrossRefGoogle Scholar
  4. 4.
    Hochster HS, Hart LL, Ramanathan RK, Childs BH, Hainsworth JD, Cohn AL, et al. Safety and efficacy of oxaliplatin and fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: results of the TREE Study. J Clin Oncol. 2008;26(21):3523–9.PubMedCrossRefGoogle Scholar
  5. 5.
    Gaya A, Tse V. A preclinical and clinical review of aflibercept for the management of cancer. Cancer Treat Rev. 2012;38(5):484–93.PubMedCrossRefGoogle Scholar
  6. 6.
    Grothey A. Results of a phase III randomized, double-blind, placebo-controlled, multicenter trial (CORRECT) of regorafenib plus best supportive care (BSC) versus placebo plus BSC in patients (pts) with metastatic colorectal cancer (mCRC) who have progressed after standard therapies. In: Gastrointestinal cancers symposium of the American Society of Clinical Oncology, San Framcisco, CA, USA, 21 Jan 2012.Google Scholar
  7. 7.
    Nordlinger B, Sorbye H, Glimelius B, Poston GJ, Schlag PM, Rougier P, et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet. 2008;371(9617):1007–16.PubMedCentralPubMedCrossRefGoogle Scholar
  8. 8.
    Sorbye H, Mauer M, Gruenberger T, Glimelius B, Poston GJ, Schlag PM, et al. Predictive factors for the benefit of perioperative FOLFOX for resectable liver metastasis in colorectal cancer patients (EORTC Intergroup Trial 40983). Ann Surg. 2012;255(3):534–9.PubMedCrossRefGoogle Scholar
  9. 9.
    Mucha P. Small intestine obstruction. Surg Clin North Am. 1987;67:597–620.PubMedGoogle Scholar
  10. 10.
    Butler JA, Cameron BL, Morrow M, Kahng K, Tom J. Small bowel obstruction in patients with a prior history of cancer. Am J Surg. 1991;162:624–8.PubMedCrossRefGoogle Scholar
  11. 11.
    NCCN Colon Cancer Guidelines (version 1.2013). National Comprehensive Cancer Network. 2013. Available at Accessed Feb 2013.
  12. 12.
    Venderbosch S, de Wilt JH, Teerenstra S, Loosveld OH, van Bochove A, Sinnige HA, et al. Prognostic value of resection of primary tumor in patients with stage IV colorectal cancer: retrospective analysis of two randomized studies and a review of the literature. Ann Surg Oncol. 2011;18(12):3252–60.PubMedCentralPubMedCrossRefGoogle Scholar
  13. 13.
    Cirocchi R, Trastulli S, Abraha I, Vettoretto N, Boselli C, Montedori A, et al. Non-resection versus resection for an asymptomatic primary tumour in patients with unresectable stage IV colorectal cancer. Cochrane Database Syst Rev. 2012;(8):CD008997.Google Scholar
  14. 14.
    McCahill LE, Yothers G, Sharif S, Petrelli NJ, Lai LL, Bechar N, et al. Primary mFOLFOX6 plus bevacizumab without resection of the primary tumor for patients presenting with surgically unresectable metastatic colon cancer and an intact asymptomatic colon cancer: definitive analysis of NSABP trial C-10. J Clin Oncol. 2012;30(26):3223–8.PubMedCentralPubMedCrossRefGoogle Scholar
  15. 15.
    Hompes D, Ruers T. Review: incidence and clinical significance of Bevacizumab-related non-surgical and surgical serious adverse events in metastatic colorectal cancer. Eur J Surg Oncol. 2011;37(9):737–46.PubMedCrossRefGoogle Scholar
  16. 16.
    Law WL, Choi HK, Lee YM, Chu KW. Palliation for advanced malignant colorectal obstruction by self-expanding metallic stents: prospective evaluation of outcomes. Dis Colon Rectum. 2004;47(1):39–43.PubMedCrossRefGoogle Scholar
  17. 17.
    Manes G, de Bellis M, Fuccio L, Repici A, Masci E, Ardizzone S, et al. Endoscopic palliation in patients with incurable malignant colorectal obstruction by means of self-expanding metal stent: analysis of results and predictors of outcomes in a large multicenter series. Arch Surg. 2011;146(10):1157–62.PubMedCrossRefGoogle Scholar
  18. 18.
    Lamazza A, Fiori E, Scillaci A, Demasi E, Pontone S, Sterpetti AV. Self-expandable metallic stents in patients with stage IV obstructing colorectal cancer. World J Surg. 2012;36(12):2931–6.PubMedCrossRefGoogle Scholar
  19. 19.
    Scheele J, Stangl T, Altendorf-Hofmann A. Hepatic metastases from colorectal carcinoma: impact of surgical resection on the natural history. Br J Surg. 1990;77:1241–6.PubMedCrossRefGoogle Scholar
  20. 20.
    Scheele J, Stangl R, Atlendorf-Hofmann A, Paul M. Resection of colorectal liver metastases. World J Surg. 1995;19(1):59–71.PubMedCrossRefGoogle Scholar
  21. 21.
    Nordlinger B, Guiguet M, Vaillant JC, Valladur P, Boudjema K, Bachellier P, et al. Surgical resection of colorectal carcinoma metastases to the liver. A prognostic scoring system to improve case selection, based on 1568 patients. Cancer. 1996;77:1254–62.PubMedCrossRefGoogle Scholar
  22. 22.
    Choti MA, Sitzmann JV, Tiburi ME, Sumetchotimetha W, Rangsin R, Schulck RD, et al. Trends in ling-term survival following liver resection for hepatic colorectal metastases. Ann Surg. 2002;235(2):759–66.PubMedCentralPubMedCrossRefGoogle Scholar
  23. 23.
    Fernandez FG, Drebin JA, Linchan DC, Dehdashti F, Siegel BA, Strasberg SM. Five year survival after resection of hepatic metastases from colorectal cancer in patients screened by positron emission tomography with F-18 fluorodeoxyglucose (FDG-PET). Ann Surg. 2004;240(3):438–47.PubMedCentralPubMedCrossRefGoogle Scholar
  24. 24.
    Pawlik TM, Scoggins CR, Zorzi D, Abdalla EK, Andres A, Eng C, et al. Effect of surgical margin status on survival and site of recurrence after hepatic resection from colorectal metastases. Ann Surg. 2005;241(5):715–22.PubMedCentralPubMedCrossRefGoogle Scholar
  25. 25.
    Tomlinson JS, Jarnagin WR, DeMatteo RP, Fong Y, Kornprat P, Gonen M, et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J Clin Oncol. 2007;25(29):4575–80.PubMedCrossRefGoogle Scholar
  26. 26.
    Scheele J, Altendorf-Hoffman A, Grube T, Hohenbreger W, Stangl R, Schmidt K. Resection of colorectal liver metastases. What prognostic factors determine patient selection? Chirurg. 2001;72(5):547–60.PubMedCrossRefGoogle Scholar
  27. 27.
    Abdalla EK, Vauthey JN, Ellis LM, Ellis V, Pollock R, Broglio KR, et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann Surg. 2004;239(6):818–25.PubMedCentralPubMedCrossRefGoogle Scholar
  28. 28.
    Sorensen SM, Mortensen FV, Nielsen DT. Radiofrequency ablation of colorectal liver metastases: long-term survival. Acta Radiol. 2007;48(3):253–8.PubMedCrossRefGoogle Scholar
  29. 29.
    Siperstein AE, Berber E, Ballem N, Parikh RT. Survival after radiofrequency ablation of colorectal liver metastases: 10-year experience. Ann Surg. 2007;246(4):559–65.PubMedCrossRefGoogle Scholar
  30. 30.
    Kennedy TJ, Cassera MA, Khajanchee YS, Diwan TS, Hammill CW, Hansen PD. Laparoscopic radiofrequency ablation for the management of colorectal liver metastases: 10-year experience. J Surg Oncol. 2013;107(4):324–8.PubMedCrossRefGoogle Scholar
  31. 31.
    Cirocchi R, Trastulli S, Boselli C, Montedori A, Cavaliere D, Parisi A, et al. Radiofrequency ablation in the treatment of liver metastases from colorectal cancer. Cochrane Database Syst Rev. 2012;(6):CD006317.Google Scholar
  32. 32.
    Pfannschmidt J, Dienemann H, Hoffmann H. Surgical resection of pulmonary metastases from colorectal cancer: a systematic review of published series. Ann Thorac Surg. 2007;84(1):324–38.PubMedCrossRefGoogle Scholar
  33. 33.
    Pfannschmidt J, Dienemann H, Hoffmann H. Reported outcome factors for pulmonary resection in metastatic colorectal cancer. J Thorac Oncol. 2010;5(6 Suppl 2):S172–8.PubMedCrossRefGoogle Scholar
  34. 34.
    Fiorentino F, Hunt I, Teoh K, Treasure T, Utley M. Pulmonary metastasectomy in colorectal cancer: a systematic review and quantitative synthesis. J R Soc Med. 2010;103(2):60–6.PubMedCentralPubMedCrossRefGoogle Scholar
  35. 35.
    Sugarbaker PH, Cunliffe WJ, Belliveau J, de Brulin EA, Graves T, Mullins RE, et al. Rationale for integrating early postoperative intraperitoneal chemotherapy into the surgical treatment of gastrointestinal cancer. Semin Oncol. 1989;16(4 Suppl 6):83–97.PubMedGoogle Scholar
  36. 36.
    Dawson LE, Russell AH, Tong D, Wisbeck WM. Adenocarcinoma of the sigmoid colon: sites of initial dissemination and clinical patterns of recurrence following surgery alone. J Surg Oncol. 1983;22(2):95–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Sugarbaker PH, Zhu BW, Sese GB, Shmookler B. Peritoneal carcinomatosis from appendiceal cancer: results in 69 patients treated by cytoreductive surgery and intraperitoneal chemotherapy. Dis Colon Rectum. 1993;36(4):323–9.PubMedCrossRefGoogle Scholar
  38. 38.
    Sugarbaker PH, Averbach AM, Jacquet P, Stuart OA, Stephens AD. Hyperthermic intraoperative intraperitoneal chemotherapy (HIIC) with mitomycin C. Surg Technol Int. 1996;5:245–9.PubMedGoogle Scholar
  39. 39.
    Verwaal VJ, van Ruth S, de Bree E, van Sloothen GW, van Tinteren H, Zoetmulder FA. Randomized trial of cytoreduction and hyperthermic intraperitoneal chemotherapy versus systemic chemotherapy and palliative surgery in patients with peritoneal carcinomatosis of colorectal cancer. J Clin Oncol. 2003;21(20):3737–43.PubMedCrossRefGoogle Scholar
  40. 40.
    Elias D, Glehen O, Pocard M, Quenet F, Goere D, Arvieux C, et al. A comparative study of complete cytoreductive surgery plus intraperitoneal chemotherapy to treat peritoneal dissemination from colon, rectum, small bowel, and nonpseudomyxoma appendix. Ann Surg. 2010;251(5):896–901.PubMedCrossRefGoogle Scholar
  41. 41.
    Elias D, Lefevre JH, Chevalier J, Brouquet A, Marchal F, Classe JM, et al. Complete cytoreductive surgery plus intraperitoneal chemohyperthermia with oxaliplatin for peritoneal carcinomatosis of colorectal origin. J Clin Oncol. 2009;27(5):681–5.PubMedCrossRefGoogle Scholar
  42. 42.
    Van Sweringen HL, Hanseman DJ, Ahmad SA, Edwards MJ, Sussman JJ. Predictors of survival in patients with high-grade peritoneal metastases undergoing cytoreductive surgery and hyperthermic intraperitoneal chemotherapy. Surgery. 2012;152(4):617–24.PubMedCrossRefGoogle Scholar
  43. 43.
    Omranipour R, Abasahi A. Ovarian metastases in colorectal cancer. Int J Gynecol Cancer. 2009;19(9):1524–8.PubMedCrossRefGoogle Scholar
  44. 44.
    Chang GJ, Kaiser AM, Mills S, Rafferty JF, Buie WD, Standards Practice Task Force of the American Society of Colon and Rectal Surgeons. Practice parameters for the management of colon cancer. Dis Colon Rectum. 2012;55(8):831–43.PubMedCrossRefGoogle Scholar
  45. 45.
    Sundermeyer ML, Meropol NJ, Rogatko A, Wang H, Cohen SJ. Changing patterns of bone and brain metastases in patients with colorectal cancer. Clin Colorectal Cancer. 2005;5(2):108–13.PubMedCrossRefGoogle Scholar
  46. 46.
    Audisio RA, Papamichael D. Treatment of colorectal cancer in older patients. Nat Rev Gastroenterol Hepatol. 2012;9(12):716–25.PubMedCrossRefGoogle Scholar
  47. 47.
    Prasad ML, Pearl RK, Abcarian H. End-loop colostomy. Surg Gynecol Obstet. 1984;158(4):380–2.PubMedGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2014

Authors and Affiliations

  1. 1.Department of SurgeryUniversity of California, IrvineOrangeUSA

Personalised recommendations